Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1994 2
1995 5
1996 2
1997 4
1998 1
1999 2
2000 6
2001 1
2002 2
2004 1
2005 3
2006 2
2009 2
2011 1
2012 2
2013 1
2014 2
2015 1
2016 1
2017 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC, Seo SI, Falconer T, Yanover C, Duarte-Salles T, Seager S, Posada JD, Shah NH, Nguyen PA, Kim Y, Hsu JC, Van Zandt M, Hsu MH, Lee HL, Ko H, Shin WG, Pratt N, Park RW, Reich CG, Suchard MA, Hripcsak G, Park CH, Prieto-Alhambra D. You SC, et al. JAMA Netw Open. 2023 Sep 5;6(9):e2333495. doi: 10.1001/jamanetworkopen.2023.33495. JAMA Netw Open. 2023. PMID: 37725377 Free PMC article.
Crude incidence rates of cancer were 14.30 events per 1000 person-years (PYs) in ranitidine users and 15.03 events per 1000 PYs among other H2RA users. ...Further research is needed on the long-term association of ranitidine with cancer development....
Crude incidence rates of cancer were 14.30 events per 1000 person-years (PYs) in ranitidine users and 15.03 events per 1000 PY …
Ranitidine as adjuvant treatment in colorectal cancer.
Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H; Danish RANX05 Colorectal Cancer Study Group. Nielsen HJ, et al. Br J Surg. 2002 Nov;89(11):1416-22. doi: 10.1046/j.1365-2168.2002.02223.x. Br J Surg. 2002. PMID: 12390384 Clinical Trial.
BACKGROUND: Results from short-term studies of histamine type 2 (H2) receptor antagonists on survival of patients with solid tumours are debatable. In this study the efficacy of the H2-receptor antagonist ranitidine on long-term survival of patients with colorectal canc …
BACKGROUND: Results from short-term studies of histamine type 2 (H2) receptor antagonists on survival of patients with solid tumours are deb …
Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage.
Valentini M, Cannizzaro R, Poletti M, Bortolussi R, Fracasso A, Testa V, Sozzi M, Fornasarig M, Bortoluzzi F, Grazioli I. Valentini M, et al. J Clin Oncol. 1995 Oct;13(10):2637-42. doi: 10.1200/JCO.1995.13.10.2637. J Clin Oncol. 1995. PMID: 7595718 Clinical Trial.
PURPOSE: The prophylactic strategy of nonsteroidal antiinflammatory drug (NSAID)-induced upper gastrointestinal (UGI) damage has largely been studied in arthritic patients, but not in cancer patients. The efficacy of misoprostol and ranitidine in the prevention of g …
PURPOSE: The prophylactic strategy of nonsteroidal antiinflammatory drug (NSAID)-induced upper gastrointestinal (UGI) damage has largely bee …
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study.
Montero Pérez O, Martinez Benavides J, González Fernandez T, Guerra Prio S, Romero Domínguez R, Mesía Nin R, Clopés Estela A. Montero Pérez O, et al. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):877-883. doi: 10.1080/17512433.2023.2238596. Epub 2023 Jul 21. Expert Rev Clin Pharmacol. 2023. PMID: 37477611 Clinical Trial.
METHODS: A cohort, multicenter, observational, prospective, and non-inferiority study, including paclitaxel-naive cancer patients, designed to determine the incidence of HRs of any grade associated with paclitaxel administration and analyze non-inferiority against the inci …
METHODS: A cohort, multicenter, observational, prospective, and non-inferiority study, including paclitaxel-naive cancer patients, de …
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.
Deva S, Jameson M. Deva S, et al. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD007814. doi: 10.1002/14651858.CD007814.pub2. Cochrane Database Syst Rev. 2012. PMID: 22895966 Review.
OBJECTIVES: To determine if H(2)RAs improve overall survival when used as pre- and/or postoperative therapy in colorectal cancer patients who have had surgical resection with curative intent. ...MAIN RESULTS: Of the six identified trials, five used cimetidine as the experi …
OBJECTIVES: To determine if H(2)RAs improve overall survival when used as pre- and/or postoperative therapy in colorectal cancer pati …
Confounding by indication?
Shapiro S. Shapiro S. Epidemiology. 1997 Jan;8(1):110-1. Epidemiology. 1997. PMID: 9116082 Clinical Trial. No abstract available.
A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group.
Primrose JN, Miller GV, Preston SR, Gokhale J, Ambrose NS, Ward UM, Mills JG, Ehsanullah RS, Darekar B. Primrose JN, et al. Gut. 1998 Jan;42(1):17-9. doi: 10.1136/gut.42.1.17. Gut. 1998. PMID: 9505879 Free PMC article. Clinical Trial.
BACKGROUND: Does the use of the histamine H2 receptor antagonist ranitidine improve the outcome of patients with gastric cancer? PATIENTS: A total of 222 patients with gastric cancer who had received radical or palliative resection or who were deemed inoperab …
BACKGROUND: Does the use of the histamine H2 receptor antagonist ranitidine improve the outcome of patients with gastric cancer …
Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial.
Alberts DS, Mason-Liddil N, Plezia PM, Roe DJ, Dorr RT, Struck RF, Phillips JG. Alberts DS, et al. J Natl Cancer Inst. 1991 Dec 4;83(23):1739-42. doi: 10.1093/jnci/83.23.1739. J Natl Cancer Inst. 1991. PMID: 1770553 Clinical Trial.
Using a randomized, double-blind, crossover study design, we have now evaluated the potential interaction of ranitidine with cyclophosphamide in seven cancer patients, who received two courses of cyclophosphamide, one with ranitidine and one with placebo. Fou …
Using a randomized, double-blind, crossover study design, we have now evaluated the potential interaction of ranitidine with cyclopho …
Reduction of postoperative immunosuppression with ranitidine in patients with cancer of the stomach or large bowel.
Altomare DF, Lupo L, Pannarale OC, Di Corcia MG, Memeo V. Altomare DF, et al. Eur J Surg. 1995 Feb;161(2):109-13. Eur J Surg. 1995. PMID: 7772628 Clinical Trial.
OBJECTIVE: To assess the effect of ranitidine on cellular immune response (and postoperative infective morbidity) in a homogeneous group of patients. ...There were no deaths in the control group, one intra-abdominal abscess, and 8 wound infections. Median hospital stay was …
OBJECTIVE: To assess the effect of ranitidine on cellular immune response (and postoperative infective morbidity) in a homogeneous gr …
The effect of ranitidine on cellular immunity in patients with multiple myeloma.
Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, Drivsholm A. Nielsen HJ, et al. Cancer Immunol Immunother. 1990;32(3):201-5. doi: 10.1007/BF01771458. Cancer Immunol Immunother. 1990. PMID: 2289214 Free PMC article. Clinical Trial.
In a double-blind, placebo-controlled study the potential impact of immunomodulation by ranitidine was studied in 20 patients with multiple myeloma. Three patients were untreated, while 17 after previous cytotoxic therapy were in a stable phase of their disease. ...Among …
In a double-blind, placebo-controlled study the potential impact of immunomodulation by ranitidine was studied in 20 patients with mu …
45 results